Invasive aspergillosis (IA) is common in allogeneic SCT recipients, with an incidence of 4-10%. The majority of these infections are diagnosed several months after SCT and they are frequently associated with GVHD. The diagnosis is difficult and often delayed. Established IA is notoriously difficult to treat with a death rate of 80-90%. This review summarises recent data on this problem to assess whether there has been any progress. 1,2 The incidence of invasive aspergillosis (IA) seems to be increasing. 3, 4 This paper summarises some recent data on IA in allogeneic SCT recipients.
cases are diagnosed relatively late after SCT. The median time to diagnosis is 3-4 months from SCT. 6, 10 A study by Wald and co-workers 3 suggests a bimodal distribution of cases. A smaller proportion was observed early (Ͻ40 days) after the transplant, while the majority of the cases were late infections with different risk factors, notably GVHD. Aspergillus fumigatus has been the most common causative organism, but invasive infections caused by Aspergillus flavus, Aspergillus niger and Aspergillus terreus have also been recorded.
Several risk factors for IA have been identified. 3, 11 These factors may be useful in identifying optimal patients for various prophylactic strategies. Neutropenia is a classical risk factor for IA, but acute GVHD and extensive chronic GVHD might be even more important. Other risk factors include previous IA, 12 CMV disease, 4 HLA mismatch, unrelated donor, T cell depletion of the graft, and care in a room without efficient air filtration. 3 Also, patients who fail to engraft are at high risk of IA. 5 
Advances in diagnosis
Symptoms and signs of IA are frequently non-specific, often leading to considerable delays in diagnosis. Fever is a common symptom, although a significant proportion of the patients are afebrile 10 probably due to the use of concomitant glucocorticoid. Respiratory symptoms and neurological symptoms and signs may also be seen in a high proportion of patients. The lungs are the most common organ affected by aspergillosis (Ͼ90%), but disseminated infection is also commonly seen in allogeneic SCT recipients. 10, 13 Bronchoalveolar lavage has a diagnostic sensitivity of 30-50% in transplant recipients. 10, 14 Radiological findings on computed tomography are often suggestive of invasive pulmonary aspergillosis (IPA) and may allow earlier diagnosis. 15 In some cases, radiologically guided fine needle lung biopsy may yield the diagnosis. 16 However, new and promising methods are likely to change diagnostic strategies in the near future.
Galactomannan, a constituent of the fungal cell wall, can be measured in urine or serum. Recently, a sensitive ELISA assay for determination of serum galactomannan has been developed. [17] [18] [19] [20] Serial measurements may allow earlier diagnosis of IA, with high sensitivity and specificity. 21 It has been suggested that two consecutive positive tests are indicative of IA in high-risk patients and an indication for radiological studies (eg high-resolution computed tomography of the chest). Prospective studies are ongoing, with serial measurements of serum galactomannan as a guide to start pre-emptive antifungal therapy in transplant recipients.
Fungal DNA can be studied from either bronchoalveolar fluid 22, 23 or serum [24] [25] [26] [27] by polymerase chain reaction (PCR). These methods are very sensitive, but false positive findings based on contamination have also been observed. In addition, these methods have to be developed separately in every center, which may limit their application to the bestresourced transplant units. Studies using serial determinations of Aspergillus DNA with PCR in serum specimens to start antifungal therapy have been initiated.
At the present time, computed tomography of the chest in high-risk patients is the method of choice to identify more or less typical radiological appearances of pulmonary aspergillosis. Both galactomannan and PCR-based methods are, at present, investigational and more prospective data are needed concerning their contribution to the earlier diagnosis of IA in allogeneic SCT recipients.
Therapeutic measures

Antifungal therapy
Amphotericin B deoxycholate (AmB) (1-1.5 mg/kg/day) has been the standard treatment of IA for decades. This drug, however, has severe side-effects which preclude its prolonged use in many allogeneic SCT recipients. The toxicity of AmB has led to the development of lipid formulations including liposomal AmB (LAMB), AmB in lipid complex (ABLC), and AmB in colloidal dispersion (ABCD). Several reports have been published on the feasibility and efficacy of LAMB, [28] [29] [30] [31] ABLC [32] [33] [34] and ABCD. 35, 36 in transplant recipients. In general, these preparations are less nephrotoxic than AmB, but current evidence suggests that their efficacy is comparable to that of AmB. A recent randomised study suggests that LAMB has fewer infusion-related side-effects than ABLC. 37 An optimal dose of various lipid formulations of AmB is not yet known. In most studies, doses ranging from 1 to 5 mg/kg/day have been used, but higher doses are also under evaluation.
Itraconazole (400-800 mg/day) is active against Aspergillus sp. 38 In allogeneic SCT recipients, oral capsules are, however, problematic. Intestinal absorption is variable and, hence, drug level monitoring is recommended. Itraconazole also has clinically important drug interactions. Recently, oral cyclodextrin solution 39 as well as intravenous formulation 40 have expanded the potential use of this drug in allogeneic transplant recipients. The main therapeutic use of itraconazole may be the long-term management of IA in patients initially successfully treated with AmB preparations. 11 Several new antifungal drugs are under clinical evaluation and some of them may soon come into routine use. Voriconazole, an azole drug, has good penetration into the central nervous system, and some responses have also been described in patients with central nervous system aspergillosis. Voriconazole improved the outcome of aspergillosis when compared to AmB or other licenced therapy. 41 A recent study showed good responses in 60% of patients with pulmonary or tracheobronchial IA. 42 Other azole drugs such as ravuconazole and posaconazole are under clinical evaluation.
Echinocandins are a new class of antifungal agents with potential broad-spectrum activity. Their action is based on the inhibition of glucan synthesis in the fungal cell wall. 43 Caspofungin has already been licenced for use in patients with invasive aspergillosis who have failed or are intolerant to earlier therapy based on a study showing activity in this patient group. 44 Other echinocandins under investigation include micafungin and anindulafungin. All these new antifungal drugs hold some promise, but their contribution to the current therapies is as yet unsettled.
Other therapies
Since immunosuppression is the major risk factor for IA, amelioration of immunosuppression is the key factor in the success of therapy. Reduction in steroid dose should be considered in all patients with IA, but discontinuation of cyclosporine may cause serious problems with GVHD.
Although not formally proven, granulocyte colony-stimulating factors are logical adjuncts to the therapy of neutropenic patients with IA. Granulocyte-macrophage colony-stimulating factor (GM-CSF) may also be useful in patients with IA, but no randomised studies are available at present. GM-CSF has the additional advantage of stimulating monocytes and macrophages, which might have some importance in these patients. Interferon gamma improves neutrophil function and has shown activity in patients with chronic granulomatous disease, 45 but has not been systematically evaluated in transplant recipients with aspergillosis.
Surgery has been suggested in transplant recipients with IA. If the patient has a single lesion in the lung, resection should be considered. 46, 47 A recent retrospective analysis suggested that patients who had had a lung resection had a better outcome than did patients who did not undergo surgery. 48 If the patient has invasive sinusitis caused by Aspergillus sp., surgery should also be considered. 49 Surgery is not optional in a significant proportion of transplant recipients due to co-morbid conditions; in these patients, new antifungals with GM-CSF might be a viable alternative.
Treatment outcome
Until now, the treatment of invasive aspergillosis in allogeneic SCT recipients has largely failed, with mortality rates of 90% or more. 11, 50 In a French series, however, six out of 27 patients (22%) were cured. 51 In our study of 20 consecutive patients with IA only two patients (10%) were cured, but an objective treatment response was observed in 37% of the patients. nervous system is common in allogeneic SCT recipients 6, 10 and is associated with a very poor outcome. 53 Treatment response is often difficult to define, although radiological studies are helpful. Serial measurements of either serum galactomannan or fungal PCR might be useful adjuncts to the assessment of treatment response in these patients.
Prophylactic measures
Since the prognosis of established IA is poor, effective prophylaxis is of paramount importance. Unfortunately, very limited data are currently available on this topic. This is partly due to the fact that allogeneic SCT recipients have been either excluded from prophylactic studies 54 or have formed only a minority of the study population. 55 Moreover, several studies have used historical cohorts for comparison, making the results less meaningful. The relative infrequency of IA even in the allogeneic setting has often led to statistically underpowered studies.
Since fungal spores are common in the environment and the route of acquisition is via the respiratory tract, a rational way of decreasing the risk of invasive infection is the use of high-efficiency particulate air filtration with or without laminar air flow. There are some data suggesting that the risk of early infections can be reduced, 3, 56 although the issue has never been studied prospectively in a randomised fashion. However, these measures are not suited to longterm use, and the risk of IA may last for 6 months from SCT or even longer in patients with chronic GVHD.
In a previous observational study in BMT recipients using prophylactic AmB inhalations, a low incidence of IA was reported. 57 A large randomised trial was subsequently started. 54 In this study, there were some problems with tolerance of AmB, and no efficacy of the regimen used was noted. However, allogeneic SCT recipients were excluded from the study. Thus, the issue of the efficacy of this approach in the allogeneic setting remained unsettled.
Itraconazole either in oral solution or intravenous formulation might be a prophylactic approach at least in highrisk patients. A recent randomised comparison between itraconazole and fluconazole showed a lower risk for invasive fungal infections in allogeneic recipients receiving itraconazole, but the incidence of IA was low in both arms. 40 Similarly, no convincing data exist on the efficacy of AmB on the prophylaxis of IA in this setting. 58 One prospective placebo-controlled study of liposomal AmB has been published, with inconclusive results. 59 Since most cases of IA in the allogeneic setting are associated with GVHD, more accurate tissue-typing methods may be useful in reducing the risk of IA. Furthermore, more effective prophylactic regimens against GVHD might reduce the risk of invasive fungal infections. 60 Secondary prophylaxis of IA in allogeneic SCT recipients with a previous history of definite or probable IA is also an important issue. A retrospective analysis suggested that patients receiving oral or intravenous antifungals had less relapses that those patients who did not. 12 The optimal secondary prophylaxis is not known, but a combination of surgery and antifungal therapy might represent the best option.
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Future perspectives
Although our therapeutic measures have been broadened, and significant advances have been made in identifying high-risk patients and diagnosing invasive infection at an earlier stage, invasive aspergillosis still remains an important issue in allogeneic transplantation. Several changes in patient characteristics as well as in transplant procedures, including higher recipient age and the continuously increasing use of unrelated 61 or mismatched donors, 62 may even increase the risk of IA. Reduced intensity-conditioning 63 has recently gained some popularity, but risk of invasive fungal infection may be as high as with conventional myeloablative conditioning. 64 Pre-emptive strategies based on the evaluation of either fungal PCR or galactomannan antigen are under investigation. The results of these trials may be of importance for future management of transplant recipients. Also, more effective treatment modalities are needed. Besides new antifungal drugs, combinations of antifungal drugs with different modes of action may also be of use. Dendritic cellmediated stimulation of lymphocytes, 65 cytokines or, in selected cases, surgery may also prove to be useful adjuncts to the treatment measures against invasive aspergillosis.
